CE-Certified Internet Activity
Moderator
Panelists
Educational Overview
Learning Objectives
Target Audience
Academic Advisor
Accreditation
Method of Instruction
Disclosure Declarations
Faculty Disclosure Declarations
Off-Label Usage Disclosure
Disclaimer
Launch Presentation
Optimizing the Use of Biologics to Achieve Goals
of Therapy in IBD
Jointly Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ)-Center for Continuing and Outreach Education and Medical Crossfire®/Liberty Communications Network.
This activity is supported by an educational grant from Centocor.
Release Date: August 2007
Expiration Date: August 31, 2008
BACK TO TOPBACK TO TOP
 |
Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Chicago, Illinois |
BACK TO TOP
 |
Russell D. Cohen, MD, FACG, AGAF Associate Professor of Medicine Department of Medicine Section of Gastroenterology University of Chicago Medical Center Chicago, Illinois |
 |
Professor Subrata Ghosh, MD, FRCP, FRCP(E) Professor of Gastroenterology Imperial College London, Hammersmith Hospital; Consultant Gastroenterologist Hammersmith Hospital London, United Kingdom |
 |
Anne M. Griffiths, MD, FRCP(C) Director, Pediatric IBD Program Hospital for Sick Children Professor of Pediatrics University of Toronto Toronto, Canada |
 |
Daniėl W. Hommes, MD Professor of Gastroenterology and Hepatology Leiden University Medical Centre Leiden, Netherlands |
 |
Sunanda V. Kane, MD, MSPH, FACG Associate Professor of Medicine University of Chicago Chicago, Illinois |
BACK TO TOPThe use of biologic agents in the treatment of patients with Crohn's disease or ulcerative colitis remains a challenge for clinicians. Presently, a number of factors regarding how such therapy can be optimized to achieve goals of therapy remain matters of discussion. For example: Does early intervention with biologics impact the natural history of these diseases? Is it necessary to continue immunosuppressant therapy after biologic therapy has been initiated in order to maintain response? What are the safety issues associated with use of biologic agents and what is their relevance to clinical practice? Is there a pharmacoeconomic advantage to using a biologic agent?
Through debate and authoritative peer exchange, this Medical Crossfire® activity, conducted in conjunction with UMDNJ, will discuss these and other issues related to the use of biologic agents for the management of patients with Crohn's disease or ulcerative colitis.
BACK TO TOPAt the conclusion of the activity, participants should be able to:
- Discuss the role of top-down versus step-up treatment in the management of Crohn's disease and ulcerative colitis.
- Evaluate the safety of biologic agents and consider how safety should factor into clinical decision-making.
- Discuss the advantages and disadvantages of concomitant immunomodulator therapy with biologic therapy.
- Describe the factors related to loss of response in patients treated with biologics.
- Describe the pharmacoeconomic advantages and disadvantages associated with the use of biologic agents for Crohn's disease and ulcerative colitis.
BACK TO TOPThis educational activity is designed for gastroenterologists and other health care practitioners interested in or involved with the management of patients with Crohn's disease or ulcerative colitis.
BACK TO TOPSteven R. Peikin, MD
Professor of Medicine
Head, Division of Gastroenterology and Liver Disease
University of Medicine & Dentistry of New Jersey—Robert Wood Johnson Medical School at Camden
The Cooper Hospital/University Medical Center
Camden, New Jersey
BACK TO TOPPhysicians
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ–Center for Continuing and Outreach Education and Medical Crossfire/Liberty Communications Network. UMDNJ–Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians.
UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim credit commensurate with the extent of their participation.
Nurses UMDNJ—Center for Continuing and Outreach Education is an approved provider of continuing nursing education by New Jersey State Nurses Association (NJSNA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This activity is awarded 1.5 contact hours (60 minute CH).
Provider approved by the California Board of Registered Nursing, Provider Number CEP 13780.
Approval status as a provider refers only to its continuing education activity and does not imply UMDNJ, NJSNA, or ANCC endorsement of any commercial products.
Pharmacists
UMDNJ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course (ACPE 374-000-07-004-H01 qualifies for 1.5 contact hours of continuing pharmacy credit, which will be awarded via mail within 4-6 weeks after successful completion of the program.
The video presentation was peer-reviewed for relevance, accuracy of content and balance of presentation by Steven R. Peikin, MD, and pilot-tested for time required for participation by Jesse Houghton, MD, Shannon Shaw, RN, and Paul Hsu, RPh.
BACK TO TOPParticipants should read the learning objectives and review either the print monograph or the video presentation in its entirety. After reviewing the material, complete the self-assessment test consisting of a series of multiple-choice questions.
The activity is complemented with references that contain the rationale for the correct answer to each self-assessment question as well as a description identifying the section of the activity that contains the correct answer, allowing participants to review the material as needed, thus finalizing their educational participation.
Upon completing this activity as designed, participants will receive a letter of credit awarding AMA PRA Category 1 CreditsTM three to four weeks after receipt of the registration, and evaluation materials.
Estimated time to complete this activity as designed is 1.5 hours.
BACK TO TOPIn accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: 1) the existence of any financial interest or other relationships with proprietary entities producing health care goods or services, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
BACK TO TOPDr. Hanauer has received grant/research support from, has been a consultant for, and has served on the scientific advisory boards of Abbott Laboratories, Centocor, Inc., Elan Pharmaceuticals, and UCB; he has also served on the speakers' bureau of Centocor, Inc.
Dr. Cohen has received grant/research support from Centocor, Inc.; has been a consultant for, and has served on the speakers' bureaus of Abbott Laboratories, Elan Pharmaceuticals, and UCB; and his spouse has stock holdings in Johnson & Johnson and is an employee of Centocor, Inc.
Dr. Ghosh has received grant/research support from Schering-Plough Corp.; has served on the scientific advisory boards of Abbott Laboratories, Centocor, Inc., Elan Pharmaceuticals, Schering-Plough Corp., and UCB; and has served on the speakers' bureaus of Abbott Laboratories, Centocor, Inc., and Schering-Plough Corp.
Dr. Griffiths has received research support from Schering Canada; has been a consultant for Centocor, Inc., Schering Canada, Schering-Plough Corp., and UCB Pharma; and has served on the speakers' bureaus of Abbott Laboratories, Schering Canada, and Schering-Plough Corp.
Dr. Hommes has been a consultant for Abbott Laboratories, Bristol-Myers Squibb, Centocor, Inc., Elan Pharmaceuticals, and Schering-Plough Corp.; and has received financial support from Abbott Laboratories, Centocor, Inc., PDL BioPharma, Schering-Plough Corp., and UCB.
Dr. Kane has received grant/research support from Procter & Gamble Pharmaceuticals and Tech Laboratories; has been a consultant for Abbott Laboratories, Centocor, Inc., Elan Pharmaceuticals, Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, and UCB; has served on the scientific advisory boards of Procter & Gamble Pharmaceuticals and Shire Pharmaceuticals; and has served on the speakers' bureaus of Abbott Laboratories, Centocor, Inc., Novartis Pharmaceuticals Corp., Procter & Gamble Pharmaceuticals, Prometheus Labs, Shire Pharmaceuticals, Solvay Pharmaceuticals, and TAP Pharmaceutical Products.
Dr. Peikin has no financial arrangements or affiliations to disclose.
Dr. Houghton, Dr. Hsu, and Ms. Shaw have no financial arrangements or affiliations to disclose.
BACK TO TOPThis program contains discussion of commercial products that are unlabeled for use or investigational uses of products not yet approved for the treatment of ulcerative colitis and/or Crohn's disease.
To review Medical Crossfire's privacy policy, click here.
To review UMDNJ's privacy policy, click here.
Please direct CME related questions to UMDNJ at 973-972-4267 or email ccoe@umdnj.org.
BACK TO TOPThe views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of Centocor, any other manufacturer of pharmaceuticals, UMDNJ, or Medical Crossfire®/Liberty Communications Network.
It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating panelist. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Click the launch button to watch the webcast. The webcast system will automatically detect your bandwidth and player settings. For help with the webcast, please visit the help page.
Copyright © 2007 by UMDNJ-Center for Continuing and Outreach Education and Liberty Communications Network. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems without permission in writing from UMDNJ-Center for Continuing and Outreach Education or Liberty Communications Network.
Medical Crossfire® is a registered trademark of Liberty Communications Network.